Seeking Alpha

More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down...

More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down 28% from the same quarter last year. R&D expenses increased nearly 50% to $9M, driven largely by higher product manufacturing costs for RP103, its treatment for cystinosis, Huntington's disease and non-alcoholic steatohepatitis, plus other supporting study expenses and employee compensation. SG&A costs also ramped up during the quarter due to marketing expenses attributed to RP103 as well.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs